Clinical application of multispectral irradiation combined with conventional therapy on acute exacerbation of chronic obstructive pulmonary disease

doi:10.3969/j.issn.1004-583X.2025.01.004

Abstract

Abstract:

Objective To investigate the efficacy of multispectral irradiation combined with conventional therapy on the acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 86 patients with AECOPD who were treated in Hebei General Hospital from January 2022 to November 2023 were selected and divided into observation group (n=42) and control group (n=44) according to a random number table. Patients in the control group were treated with conventional therapy, and those in the observation group were treated with multispectral irradiation plus conventional therapy. The clinical data within 24 hours before and after treatment were compared between the two groups. Results There were significant differences in the modified medical research council score, alkaline phosphatase, serum amyloid A, white blood cell, absolute neutrophil count, 6-meter walking test, vitamin D, Ca²⁺, and oxygenation index between groups after treatment (P<0.05), while there were no significant differences in the Global Initiative for Chronic Obstructive Lung Disease grading, C-reactive protein, forced expiratory volume in one second/forced vital capacity, forced expiratory volume in 1 second percentage of predicted, P⁵⁺, and eosinophil(P>0.05). Conclusion The application of multispectral irradiation combined with conventional therapy on AECOPD patients can better increase their oxygen content, subjective perception of breathing difficulties, vitamin D levels, exercise endurance, and inflammatory response.

Key words: pulmonary disease, chronic obstructive, physical therapy, multispectral irradiation therapy, vitamin D

CLC Number:

R563.9

Zhou Zhiming, Ru Yi, Li Ping, Ping Fen. Clinical application of multispectral irradiation combined with conventional therapy on acute exacerbation of chronic obstructive pulmonary disease[J]. Clinical Focus, 2025, 40(1): 27-32.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2025.01.004

https://huicui.hebmu.edu.cn/EN/Y2025/V40/I1/27

Figures/Tables 3

Tab.1 General information between groups

组别	例数	年龄(岁)	性别[例(%)]		身高(m)	体重(kg)	BMI(kg/m²)
组别	例数	年龄(岁)	男性	女性	身高(m)	体重(kg)	BMI(kg/m²)
观察组	42	70.00(64.00,74.00)	31(73.8)	11(26.2)	1.65±0.08	65.30±13.33	24.02±4.55
对照组	44	70.00(64.75,73.25)	35(79.5)	9(20.5)	1.67±0.08	65.35±12.91	23.49±3.95
$Z$ /χ²/ $t$ 值		-0.113	0.396		-0.876	0.104	0.620
$P$ 值		0.910	0.529		0.384	0.918	0.537

Tab.1 General information between groups

组别	例数	年龄(岁)	性别[例(%)]		身高(m)	体重(kg)	BMI(kg/m²)
组别	例数	年龄(岁)	男性	女性	身高(m)	体重(kg)	BMI(kg/m²)
观察组	42	70.00(64.00,74.00)	31(73.8)	11(26.2)	1.65±0.08	65.30±13.33	24.02±4.55
对照组	44	70.00(64.75,73.25)	35(79.5)	9(20.5)	1.67±0.08	65.35±12.91	23.49±3.95
$Z$ /χ²/ $t$ 值		-0.113	0.396		-0.876	0.104	0.620
$P$ 值		0.910	0.529		0.384	0.918	0.537

Tab.2 The severity of disease between groups before and after treatment

组别	例数		mMRC量表评分(分)		6MWT(m)				FEV₁/FVC
组别	例数		治疗前	治疗后	治疗前		治疗后		治疗前		治疗后
观察组	42		3(3,3)	3(2,3)^*	226.90±60.74		306.43±73.49^*		0.46±0.11		0.50±0.14^*
对照组	44		3(3,3)	3(3,3)	210.24±88.30		216.50(169.25,303.50)^*		0.48±0.12		0.48±0.11
$Z$ / $t$ 值			-1.260	-2.728	0.798		-3.858		-0.736		1.006
$P$ 值			0.208	0.006	0.427		<0.001		0.463		0.317
组别		FEV₁%pred						GOLD分级
组别		治疗前				治疗后		治疗前		治疗后
观察组		40.70(36.48,43.90)				46.30(38.78,54.83)^*		3(3,3)		3(2,3)^*
对照组		40.60(36.11,49.70)				43.45(38.26,57.70)^*		3(2.75,3)		3(2,3)
$Z$ / $t$ 值		-0.436				-0.799		-1.037		-0.518
$P$ 值		0.663				0.424		0.300		0.605

Tab.2 The severity of disease between groups before and after treatment

组别	例数		mMRC量表评分(分)		6MWT(m)				FEV₁/FVC
组别	例数		治疗前	治疗后	治疗前		治疗后		治疗前		治疗后
观察组	42		3(3,3)	3(2,3)^*	226.90±60.74		306.43±73.49^*		0.46±0.11		0.50±0.14^*
对照组	44		3(3,3)	3(3,3)	210.24±88.30		216.50(169.25,303.50)^*		0.48±0.12		0.48±0.11
$Z$ / $t$ 值			-1.260	-2.728	0.798		-3.858		-0.736		1.006
$P$ 值			0.208	0.006	0.427		<0.001		0.463		0.317
组别		FEV₁%pred						GOLD分级
组别		治疗前				治疗后		治疗前		治疗后
观察组		40.70(36.48,43.90)				46.30(38.78,54.83)^*		3(3,3)		3(2,3)^*
对照组		40.60(36.11,49.70)				43.45(38.26,57.70)^*		3(2.75,3)		3(2,3)
$Z$ / $t$ 值		-0.436				-0.799		-1.037		-0.518
$P$ 值		0.663				0.424		0.300		0.605

Tab.3 Laboratory data between groups before and after treatment

组别	例数		VD(ng/ml)						Ca²⁺(mmol/L)							P⁵⁺(mmol/L)
组别	例数		治疗前			治疗后			治疗前				治疗后			治疗前			治疗后
观察组	42		19.08±4.97			24.12±4.98^*			2.15(2.08,2.22)				2.26±0.09^*			1.12±0.19			1.21±0.22^*
对照组	44		20.19±5.62			18.32±5.14^*			2.19(2.10,2.25)				2.15(2.07,2.27)^*			1.11±0.21			1.10±0.24
$Z$ / $t$ 值			-1.218			4.992			-1.505				-3.644			-0.250			1.555
$P$ 值			0.226			<0.001			0.132				<0.001			0.803			0.124
组别	ALP(U/L)							OI(mmHg)							CRP(mg/L)
组别	治疗前				治疗后			治疗前			治疗后				治疗前			治疗后
观察组	69.10(56.83,81.03)				59.70(53.15,69.68)^*			328.95±47.67			413.45±46.48^*				17.99(6.82,41.32)			2.78(1.46,4.27)^*
对照组	70.55±19.04				70.05±16.70			338.00±51.51			355.00±42.47^*				9.11(0.92,23,96)			3.00(0.72,17.18)^*
$Z$ / $t$ 值	-0.251				-2.402			-0.979			5.847				-1.858			-0.658
$P$ 值	0.802				0.016			0.330			<0.001				0.063			0.511
组别		SAA(mg/L)					WBC(×10⁹/L)					ANC(×10⁹/L)					EOS(%)
组别		治疗前		治疗后			治疗前			治疗后		治疗前		治疗后			治疗前			治疗后
观察组		46.08 (15.04,88.55)		2.62 (1.68,4.26)^*			9.05±3.01			6.11 (4.64,7.85)^*		6.91±2.84		3.94 (2.97,5.28)^*			0.85 (0.10,2.15)			2.40 (1.08,3.43)^*
对照组		14.14 (2.30,77.03)		8.09 (1.74,56.94)^*			7.32 (6.12,9.52)			7.05 (5.78,9.13)		5.58 (3.90,7.72)		4.83 (3.76,6.40)^*			1.25 (0.38,2.73)			1.55 (0.28,3.48)
$Z$ / $t$ 值		-1.629		-2.393			-1.654			-2.626		-1.391		-2.307			-1.283			-1.504
$P$ 值		0.103		0.017			0.098			0.009		0.164		0.021			0.200			0.133

Tab.3 Laboratory data between groups before and after treatment

组别	例数		VD(ng/ml)						Ca²⁺(mmol/L)							P⁵⁺(mmol/L)
组别	例数		治疗前			治疗后			治疗前				治疗后			治疗前			治疗后
观察组	42		19.08±4.97			24.12±4.98^*			2.15(2.08,2.22)				2.26±0.09^*			1.12±0.19			1.21±0.22^*
对照组	44		20.19±5.62			18.32±5.14^*			2.19(2.10,2.25)				2.15(2.07,2.27)^*			1.11±0.21			1.10±0.24
$Z$ / $t$ 值			-1.218			4.992			-1.505				-3.644			-0.250			1.555
$P$ 值			0.226			<0.001			0.132				<0.001			0.803			0.124
组别	ALP(U/L)							OI(mmHg)							CRP(mg/L)
组别	治疗前				治疗后			治疗前			治疗后				治疗前			治疗后
观察组	69.10(56.83,81.03)				59.70(53.15,69.68)^*			328.95±47.67			413.45±46.48^*				17.99(6.82,41.32)			2.78(1.46,4.27)^*
对照组	70.55±19.04				70.05±16.70			338.00±51.51			355.00±42.47^*				9.11(0.92,23,96)			3.00(0.72,17.18)^*
$Z$ / $t$ 值	-0.251				-2.402			-0.979			5.847				-1.858			-0.658
$P$ 值	0.802				0.016			0.330			<0.001				0.063			0.511
组别		SAA(mg/L)					WBC(×10⁹/L)					ANC(×10⁹/L)					EOS(%)
组别		治疗前		治疗后			治疗前			治疗后		治疗前		治疗后			治疗前			治疗后
观察组		46.08 (15.04,88.55)		2.62 (1.68,4.26)^*			9.05±3.01			6.11 (4.64,7.85)^*		6.91±2.84		3.94 (2.97,5.28)^*			0.85 (0.10,2.15)			2.40 (1.08,3.43)^*
对照组		14.14 (2.30,77.03)		8.09 (1.74,56.94)^*			7.32 (6.12,9.52)			7.05 (5.78,9.13)		5.58 (3.90,7.72)		4.83 (3.76,6.40)^*			1.25 (0.38,2.73)			1.55 (0.28,3.48)
$Z$ / $t$ 值		-1.629		-2.393			-1.654			-2.626		-1.391		-2.307			-1.283			-1.504
$P$ 值		0.103		0.017			0.098			0.009		0.164		0.021			0.200			0.133

References 38

[1]	Islam S, Sarkar NK, Mujahid AA, et al. Association of serum vitamin D (25OHD) level with acute exacerbation of chronic obstructive pulmonary disease[J]. Mymensingh Med J, 2019, 28(2):441-448. pmid: 31086164
[2]	王凤燕, 张冬莹, 梁振宇, 等. 面向全科医生的《慢性阻塞性肺疾病诊治指南(2021年修订版)》解读[J]. 中国全科医学, 2021, 24(29):3660-3663. doi: 10.12114/j.issn.1007-9572.2021.01.304
[3]	Kokturk N, Baha A, Oh YM, et al. Vitamin D deficiency: What does it mean for chronic obstructive pulmonary disease (COPD)? A compherensive review for pulmonologists[J]. Clin Respir J, 2018, 12(2):382-397. doi: 10.1111/crj.12588 pmid: 27925404
[4]	陈月存, 杨浩亮, 连新宇. LED多波段光谱治疗仪的研制[J]. 中国医疗设备, 2018, 33(7):27-29.
[5]	魏伊函, 阿衣古丽·衣明江, 谢宛润, 等. 多波段光谱治疗仪对中老年患者维生素D水平的影响[J]. 新疆医学, 2020, 50(7):712-714.
[6]	安经克, 茹意, 王亚辉, 等. 多波段光谱治疗仪治疗中老年患者原发性骨质疏松症疼痛[J]. 中国误诊学杂志, 2018, 13(8):349-352.
[7]	Kim D. The role of vitamin D in thyroid diseases[J]. Int J Mol Sci, 2017, 18(9):1949.
[8]	Morita D, Higuchi Y, Makida K, et al. Effects of ultraviolet irradiation with a LED device on bone metabolism associated with vitamin D deficiency in senescence-accelerated mouse P6[J]. Heliyon, 2020, 6(2):e3499.
[9]	吴梅, 张巍. 不同紫外线辐射剂量率对大鼠血清25-(OH)D水平及皮肤效应的影响[J]. 中国骨质疏松杂志, 2017, 23(7):870-873.
[10]	Casabona A, Valle MS, Laudani L, et al. Is the power spectrum of electromyography signal a feasible tool to estimate muscle fiber composition in patients with COPD?[J]. J Clin Med, 2021, 10(17):3815.
[11]	Nishiki K, Nojiri M, Kato R, et al. Serum creatinine/cystatin C ratio associated with cross-sectional area of erector spinae muscles and pulmonary function in patients with chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:3513-3524.
[12]	Valle MS, Russo C, Casabona A, et al. Anti-inflammatory role of vitamin D in muscle dysfunctions of patients with chronic obstructive pulmonary disease: A comprehensive review[J]. Minerva Med, 2023, 114(3):357-371.
[13]	Jorde I, Stegemann-Koniszewski S, Papra K, et al. Association of serum vitamin D levels with disease severity, systemic inflammation, prior lung function loss and exacerbations in a cohort of patients with chronic obstructive pulmonary disease (COPD)[J]. J Thorac Dis, 2021, 13(6):3597-3609. doi: 10.21037/jtd-20-3221 pmid: 34277053
[14]	Guo J, Chen Y, Zhang W, et al. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis[J]. Int J Surg, 2020, 78:28-35. doi: S1743-9191(20)30299-5 pmid: 32304896
[15]	Cookson MW, Ryan SL, Seedorf GJ, et al. Antenatal vitamin D preserves placental vascular and fetal growth in experimental chorioamnionitis due to intra-amniotic endotoxin exposure[J]. Am J Perinatol, 2018, 35(13):1260-1270. doi: 10.1055/s-0038-1642033 pmid: 29715698
[16]	李娜, 王美霞, 周晋萌, 等. 维生素D对脓毒性休克导致急性呼吸窘迫综合征患者的干预价值研究[J]. 中华危重症医学杂志(电子版), 2020, 13(5):321-327.
[17]	贾丹兵, 李乃民, 唐立明, 等. 红光照射对人体抗疲劳能力的影响[J]. 解放军医学杂志, 2007, (10):1077-1078.
[18]	Dominguez LJ, Farruggia M, Veronese N, et al. Vitamin D sources, metabolism, and deficiency: Available compounds and guidelines for its treatment[J]. Metabolites, 2021, 11(4):255.
[19]	Mungai L, Mohammed Z, Maina M, et al. Vitamin D review: The low hanging fruit for human health[J]. J Nutr Metab, 2021, 2021:6335681.
[20]	Rao CM, Singh P, Maikap D, et al. Musculoskeletal disorders in chronic obstructive airway diseases: A neglected clinical entity[J]. Mediterr J Rheumatol, 2021, 32(2):118-123. doi: 10.31138/mjr.32.2.118 pmid: 34447907
[21]	Recio IJ, Diez-Manglano J, Lopez GF, et al. Management of the COPD patient with comorbidities: An experts recommendation document[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15:1015-1037.
[22]	刘凌琳, 章陈晨, 熊玮. 阿仑膦酸钠联合钙尔奇D治疗COPD合并骨质疏松的疗效及对肺功能的影响[J]. 中国老年学杂志, 2021, 41(16):3426-3429.
[23]	Sertpoyraz FM, Deniz S. Bone mineral density and vitamin D levels in patients with group a COPD[J]. Aging Male, 2020, 23(5):873-878. doi: 10.1080/13685538.2019.1612869
[24]	LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2022, 33(10):2049-2102. doi: 10.1007/s00198-021-05900-y pmid: 35478046
[25]	Iamartino L, Brandi ML. The calcium-sensing receptor in inflammation: Recent updates[J]. Front Physiol, 2022, 13:1059369.
[26]	Dzik KP, Kaczor JJ. Mechanisms of vitamin D on skeletal muscle function: Oxidative stress, energy metabolism and anabolic state[J]. Eur J Appl Physiol, 2019, 119(4):825-839. doi: 10.1007/s00421-019-04104-x pmid: 30830277
[27]	Modesti L, Danese A, Angela Maria Vitto V, et al. Mitochondrial Ca²⁺ signaling in health, disease and therapy[J]. Cells, 2021, 10(6):1317.
[28]	Latham CM, Brightwell CR, Keeble AR, et al. Vitamin D promotes skeletal muscle regeneration and mitochondrial health[J]. Front Physiol, 2021, 12:660498.
[29]	Rajab HA. The effect of vitamin D level on parathyroid hormone and alkaline phosphatase[J]. Diagnostics (Basel), 2022, 12(11):2828.
[30]	Tariq S, Tariq S, Shahzad M. Association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal females[J]. Pak J Med Sci, 2021, 37(2):384-388. doi: 10.12669/pjms.37.2.3907 pmid: 33679918
[31]	Zhang G, Zhu J, Zhang Q, et al. Effects of high viscosity bone cement percutaneous vertebroplasty on pain, bone specific alkaline phosphatase, type-I collage cross-linked-telopeptide and boneglaprotein levels in patients with osteoporotic vertebral compression fractures[J]. Pak J Med Sci, 2022, 38(6):1552-1556. doi: 10.12669/pjms.38.6.5828 pmid: 35991267
[32]	de Paula-Silva M, Broering MF, Scharf P, et al. Red light-emitting diode treatment improves tissue recovery in DSS-induced colitis in mice[J]. J Photochem Photobiol B, 2020, 212:112018.
[33]	Lamparello AJ, Namas RA, Constantine G, et al. A conceptual time window-based model for the early stratification of trauma patients[J]. J Intern Med, 2019, 286(1):2-15. doi: 10.1111/joim.12874 pmid: 30623510
[34]	Chung H, Dai T, Sharma SK, et al. The nuts and bolts of low-level laser (light) therapy[J]. Ann Biomed Eng, 2012, 40(2):516-533. doi: 10.1007/s10439-011-0454-7 pmid: 22045511
[35]	Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system[J]. Nat Rev Immunol, 2013, 13(3):190-198. doi: 10.1038/nri3386 pmid: 23391992
[36]	Fernandez LG, Raposo B, Lagerquist M, et al. Vitamin D3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases[J]. Proc Natl Acad Sci U S A, 2020, 117(40):24986-24997.
[37]	Souto FJ, de Andrade AS, Ribeiro FM, et al. Impact of vitamin D deficiency on increased blood eosinophil counts[J]. Hematol Oncol Stem Cell Ther, 2018, 11(1):25-29. doi: S1658-3876(17)30093-6 pmid: 28830802
[38]	王敏, 张茜, 徐桂铃, 等. 健康人群和慢性阻塞性肺疾病患者的血清维生素D与血嗜酸性粒细胞计数的关系[J]. 南方医科大学学报, 2023, 43(5):727-732. doi: 10.12122/j.issn.1673-4254.2023.05.07